decoding her2 in nsclc: advances in biomarker testing and targeted therapies
Published 2 months ago • 71 plays • Length 36:45Download video MP4
Download video MP3
Similar videos
-
33:28
novel targeted therapies for nsclc: exploring her2 dysregulation
-
37:44
deciphering the data in egfr - mutant nsclc
-
36:48
personalized therapy for nsclc: biomarker testing, treatment & management in met alterations
-
40:57
expanding her2 horizons: implications for nsclc and beyond
-
58:30
the potential of her2-, her3-, and trop2-targeted therapies to address unmet needs in advanced nsclc
-
1:24:29
optimizing advanced nsclc biomarker testing, treatment and management session 2
-
58:27
addressing key targets in advanced nsclc: her2-, her3-, and trop2-targeted therapies
-
57:49
understanding her2 alterations in advanced non-squamous nsclc
-
1:39:03
everything you need to know about biomarker testing and treatment of genomically altered nsclc
-
1:14:14
fine-tuning biomarker testing to identify and target ret fusions in nsclc
-
59:37
refining biomarker testing and targeted treatment of nsclc with egfr mutations
-
7:00
landscape of biomarker testing for nsclc
-
2:07
her 2 mutation testing in lung cancer
-
33:52
keynote lecture: targeted therapies in lung cancer 2.0 – advances and promises
-
6:31
gracecast - treatment options for patients with advanced nsclc and a her2- erbb2 mutation
-
6:29
case based panel discussion nsclc – does a positive her2 mutation effect treatment decisions?
-
31:17
molecular testing and the role of her2 in managing advanced colorectal cancer
-
56:16
biomarker testing for lung cancer webinar
-
3:26
lung cancer diagnosis: her2 mutation